Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fujifilm Diosynth Biotechnologies Expands Cell-Culture Capacity


Fujifilm Diosynth Biotechnologies will expand its cell-culture manufacturing capabilities by adding two, 2000-L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.

The new reactors will complement the range of vessels at both sites, adding further flexibility for customer requirements. Each site currently operates 1000-L single-use bioreactors with 250-L to 1000-L operating volumes, with an additional 200-L single-use bioreactor in the UK, and a 2000-L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.

"The addition of these two new bioreactors will meet the demand we are seeing for a 2000-L platform, and offer a cost-effective, low-risk route to market through 'scaling-out' from early phase to commercial manufacture," said Steve Bagshaw, CEO Fujifilm Diosynth Biotechnologies, in a press release. The new bioreactors are expected to be operational by November 2014 in the US and in the UK in January 2015.

Source: Fujifilm Diosynth Biotechnologies

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here